New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal ...

Merck , known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has approved an updated label for VYTORIN® that includes results from the Study of Heart and Renal Protection .

What You Must Know About Heart Disease

Today is Wear Red Day, a campaign by the American Heart Association to raise awareness among women of an illness that kills more women than all cancers combined. At this very moment 8 million women are living in the United States with heart disease.

Heart Disease: What You Should Know

Today is Wear Red Day, a campaign by the American Heart Association to raise awareness among women of an illness that kills more women than all cancers combined. At this very moment 8 million women are living in the United States with heart disease.

Press Release

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an updated label for VYTORIN® (ezetimibe/simvastatin) that includes results from the S tudy of H eart a nd R enal P rotection (SHARP). In SHARP, VYTORIN 10/20 mg lowered LDL cholesterol in patients with moderate to severe chronic kidney disease (CKD ...

Experts discuss potential benefits of raising HDL - Cardiology Today

Experts discuss potential benefits of raising HDL Cardiology Today HDL increased in the niacin group from 35 mg/dL to 42 mg/dL; triglyceride levels improved from 164 mg/dL to 122 mg/dL and LDL levels from 74 mg/dL to 62 mg/dL. HDL was also increased in the placebo group, creating only a 4 mg/dL difference between the ...